<?xml version="1.0" encoding="UTF-8"?>
<ref id="B18">
 <label>18.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Chan</surname>
    <given-names>JF</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Yip</surname>
    <given-names>CC</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>To</surname>
    <given-names>KK</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated 
   <italic>in vitro</italic> and with clinical specimens
  </article-title>. 
  <source>J. Clin. Microbiol.</source>
  <volume>58</volume>(
  <issue>5</issue>), 
  <fpage>e00310</fpage>–
  <lpage>20</lpage> (
  <year>2020</year>). 
  <pub-id pub-id-type="pmid">32132196</pub-id>
 </mixed-citation>
 <note>
  <p>• Compares the performance of three novel real-time RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S) and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay. The results showed that the COVID-19-RdRp/Hel assay had the lowest limit of detection 
   <italic>in vitro</italic> and did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens. The positive rate of RdRp/Hel assay is higher than that of RdRp-P2 assay. The study may provide a sensitive RdRp/Hel assay to improve the laboratory diagnosis.
  </p>
 </note>
</ref>
